Skip to main content
. 2022 May 25;25(1):146–156. doi: 10.1093/neuonc/noac139

Fig. 2.

Fig. 2

Best response per RANO criteria and percentage change from baseline following olutasidenib therapy. (A) Investigator assessment using RANO and (B) volumetric assessments of tumor burden by central review. Color-coding of best response is provided according to RANO evaluation for both panels. Changes exceeding 100% are reported as 100%. BICR, blinded independent central review; PD, progressive disease; PR, partial response; RANO, Response Assessment in Neuro-Oncology; SD, stable disease.